You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Last Updated: September 26, 2023

PURIXAN Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

When do Purixan patents expire, and what generic alternatives are available?

Purixan is a drug marketed by Nova Labs Ltd and is included in one NDA.

The generic ingredient in PURIXAN is mercaptopurine. There are ten drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the mercaptopurine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Purixan

A generic version of PURIXAN was approved as mercaptopurine by DR REDDYS LABS SA on February 11th, 2004.

  Try a Trial

Drug patent expirations by year for PURIXAN
Drug Prices for PURIXAN

See drug prices for PURIXAN

Recent Clinical Trials for PURIXAN

Identify potential brand extensions & 505(b)(2) entrants

National Cancer Institute (NCI)Phase 3
Massachusetts General HospitalPhase 1
Millennium Pharmaceuticals, Inc.Phase 1

See all PURIXAN clinical trials

Pharmacology for PURIXAN

US Patents and Regulatory Information for PURIXAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Nova Labs Ltd PURIXAN mercaptopurine SUSPENSION;ORAL 205919-001 Apr 28, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for PURIXAN

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Nova Laboratories Ireland Limited Xaluprine (previously Mercaptopurine Nova Laboratories) mercaptopurine EMEA/H/C/002022
Xaluprine is indicated for the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children.
Authorised no no no 2012-03-09
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.